| Title： | Clinical practice guideline on treating community-acquired pneumonia in adult patients with Chinese patent medicines |
| Edition： | Original |
| Classification： | Traditional Chinese Medicine guideline |
| Field： | Treatment |
| Countries and regions： | China |
| Guidelines users： | This guideline can be applied to medical personnel, public health personnel, scientific research works who treat community-acquired pneumonia. |
| Evidence classification method： | GRADE provides a way to assess the quality of evidence and the strength of recommendations for clinical practice guidelines. We will import the evidence of Chinese patent medicine for the treatment of adult community-acquired pneumonia into the GRAED system, collect and evaluate the quality of the evidence, make a summary of the evidence, and finally form a recommendation opinion. We evaluated the quality of evidence based on the risk of bias, inconsistency, indirectness, imprecision, and publication bias. The quality of evidence was classified as high, moderate, low, or very low quality. Moreover, comprehensively consider the balance of benefit and harms, evidence quality, cost, clinical feasibility, availability and clinical acceptability according to GRADE method suggestions. The recommendation intensity of recommendations is divided into "strong recommendation" and "weak recommendation". |
| Development unit： | The First Affiliated Hospital of Henan University of Chinese Medicine |
| Registration time: | 2021-06-15 |
| Registration number： | IPGRP-2021CN155 |
| Purpose of the guideline: | Community-acquired pneumonia is a common infectious disease threatening human health, imposes a huge burden on society and individuals. Antimicrobial agents used to treat CAP are prone to drug-resistant strains. Despite the continuous progress in diagnostic techniques and the continuous introduction of new antimicrobial agents, the morbidity and fatality rates of CAP remain high. The adjuvant treatment of CAP with Chinese patent medicine has unique advantages, which can play the role of reducing toxicity and enhancing efficacy, and its efficacy has been confirmed in clinical practice and literature. However, there is a lack of evidence-based medicine evidence evaluation and treatment recommendation, and there are no guidelines or standards to follow and refer to, which to some extent limits the efficacy of proprietary Chinese medicine in treating CAP. Therefore, it is necessary to develop guidelines for clinical application of proprietary Chinese medicine in CAP, so as to fully promote the application of proprietary Chinese medicine in CAP, fully regulate clinical diagnosis and treatment, improve the treatment level of CAP, and reduce the burden of disease. |
Latest registration
